| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Drs. Johnson and Panitch), University of Maryland, Baltimore, MD; the Department of Neurology (Dr. Brooks), University of Wisconsin, Madison, WI; the Department of Neurology (Dr. Cohen), University of Pennsylvania, Philadelphia, PA the Department of Neurology (Dr. Ford), University of New Mexico, Albuquerque, NM; the Department of Neurology (Drs. Goldstein and Vollmer), Yale University, New Haven, CT; the Department of Neurology (Dr. Lisak), Wayne State University, Detroit, MI; the Department of Neurology (Dr. Myers), University of California, Los Angeles, CA; the Department of Neurology (Dr. Rose), University of Utah and the Veterans Administration Medical Center, Salt Lake City, UT; the Department of Neurology (Dr. Schiffer), University of Rochester, Rochester, NY; the Department of Neurology (Dr. Weiner), University of Southern California, Los Angeles, CA; and the Department of Neurology (Dr. Wolinsky), University of Texas, Houston, TX.
Address correspondence and reprint requests to Dr. Kenneth P. Johnson, Department of Neurology, N4W46, University of Maryland Hospital, 22 South Greene Street, Baltimore, MD 21201.
we studied copolymer 1 (Copaxone) in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple sclerosis (MS). Two hundred fifty-one patients were randomized to receive copolymer 1 (n = 125) or placebo (n = 126) at a dosage of 20 mg by daily subcutaneous injection for 2 years. The primary end point was a difference in the MS relapse rate. The final 2-year relapse rate was 1.19 ± 0.13 for patients receiving copolymer 1 and 1.68 ± 0.13 for those receiving placebo, a 29% reduction in favor of copolymer 1 (p = 0.007) (annualized rates = 0.59 for copolymer 1 and 0.84 for placebo). Trends in the proportion of relapse-free patients and median time to first relapse favored copolymer 1. Disability was measured by the Expanded Disability Status Scale (EDSS), using a two-neurologist (examining and treating) protocol. When the proportion of patients who improved, were unchanged, or worsened by 
1 EDSS step from baseline to conclusion (2 years) was evaluated, significantly more patients receiving copolymer 1 were found to have improved and more receiving placebo worsened (p = 0.037). Patient withdrawals were 19 (15.2%) from the copolymer 1 group and 17 (13.5%) from the placebo group at approximately the same intervals. The treatment was well tolerated. The most common adverse experience was an injection-site reaction. Rarely, a transient self-limited systemic reaction followed the injection in 15.2% of those receiving copolymer 1 and 3.2% of those receiving placebo. This reaction was characterized by flushing or chest tightness with palpitations, anxiety, or dyspnea and commonly lasted for 30 seconds to 30 minutes. This rigorous study confirmed the findings of a previous pilot trial and demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting MS in a well-tolerated fashion.
*See pages 1275 and 1276 for the Copolymer 1 Multiple Sclerosis Study Group participants.
Supported by the Federal Food and Drug Administration Orphan Drug Program no. FD-R000559-01, the National Multiple Sclerosis Society no. RG 2202-A-6, and Teva Pharmaceutical Industries, Ltd., Petah Tiqva, Israel.
Presented a t the annual meeting of the American Neurological Association, San Francisco, October 1994.
Received April 27, 1995. Accepted in final form May 1, 1995
This article has been cited by other articles:
|
|
 |
|
  P. K Coyle and D. R Jeffery Clinical efficacy and benefit of natalizumab Multiple Sclerosis, November 1, 2009; 15(4_suppl): S7 - S15. [Abstract] [PDF]
|
|
|
|
|
|
L. Metz, D. Li, A. Traboulsee, M. Myles, P. Duquette, J. Godin, M. Constantin, and V. Yong Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial Multiple Sclerosis, October 1, 2009; 15(10): 1183 - 1194. [Abstract] [PDF]
|
|
|
|
|
|
X. Montalban, J. Sastre-Garriga, M. Tintore, L. Brieva, F. Aymerich, J. Rio, J. Porcel, C. Borras, C. Nos, and A. Rovira A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis Multiple Sclerosis, October 1, 2009; 15(10): 1195 - 1205. [Abstract] [PDF]
|
|
|
|
 |
|
 E. C. Klawiter, A. H. Cross, and R. T. Naismith The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%? Neurology, September 22, 2009; 73(12): 984 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Bar-Or, J Oger, E Gibbs, M Niino, T Aziz, C Renoux, S Alatab, F. Shi, D Campagnolo, F Jalili, et al. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Multiple Sclerosis, August 1, 2009; 15(8): 959 - 964. [Abstract] [PDF]
|
|
|
|
|
|
R. Rudick, C. Polman, J. Cohen, M. Walton, A. Miller, C Confavreux, F. Lublin, M Hutchinson, P. O'Connor, S. Schwid, et al. Assessing disability progression with the Multiple Sclerosis Functional Composite Multiple Sclerosis, August 1, 2009; 15(8): 984 - 997. [Abstract] [PDF]
|
|
|
|
|
|
W. Carroll Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit Multiple Sclerosis, August 1, 2009; 15(8): 951 - 958. [Abstract] [PDF]
|
|
|
|
|
|
O. A. Khan, A. Tselis, A. Boster, F. Fazekas, F.D. Lublin, D. Li, M.S. Freedman, H.-P. Hartung, P. Rieckmann, P. Soelberg Sorensen, et al. INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL Neurology, June 16, 2009; 72(24): 2134 - 2135. [Full Text] [PDF]
|
|
|
|
|
|
D. Cadavid, L. J. Wolansky, J. Skurnick, J. Lincoln, J. Cheriyan, K. Szczepanowski, S. S. Kamin, A. R. Pachner, J. Halper, and S. D. Cook Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study Neurology, June 9, 2009; 72(23): 1976 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Call, X. Xing, G. D. Cuny, N. P. Seth, D. M. Altmann, L. Fugger, M. Krogsgaard, R. L. Stein, and K. W. Wucherpfennig In Vivo Enhancement of Peptide Display by MHC Class II Molecules with Small Molecule Catalysts of Peptide Exchange J. Immunol., May 15, 2009; 182(10): 6342 - 6352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Burger, N. Molnarfi, M. S. Weber, K. J. Brandt, M. Benkhoucha, L. Gruaz, M. Chofflon, S. S. Zamvil, and P. H. Lalive Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1{beta} in human monocytes and multiple sclerosis PNAS, March 17, 2009; 106(11): 4355 - 4359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Goodman, H. Rossman, A. Bar-Or, A. Miller, D. H. Miller, K. Schmierer, F. Lublin, O. Khan, N. M. Bormann, M. Yang, et al. GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study Neurology, March 3, 2009; 72(9): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Broadley, D Vanags, B Williams, B Johnson, D Feeney, L Griffiths, S Shakib, G Brown, A Coulthard, P Mullins, et al. Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 329 - 336. [Abstract] [PDF]
|
|
|
|
 |
|
 M. P. Gorman, B. C. Healy, M. Polgar-Turcsanyi, and T. Chitnis Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis Arch Neurol, January 1, 2009; 66(1): 54 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Gajofatto, P Bacchetti, B Grimes, A High, and E Waubant Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis Multiple Sclerosis, January 1, 2009; 15(1): 50 - 58. [Abstract] [PDF]
|
|
|
|
 |
|
 A. L. Barnard, A. P. Chidgey, C. C. Bernard, and R. L. Boyd Androgen depletion increases the efficacy of bone marrow transplantation in ameliorating experimental autoimmune encephalomyelitis Blood, January 1, 2009; 113(1): 204 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Goodin Disease-modifying therapy in multiple sclerosis: Update and clinical implications Neurology, December 9, 2008; 71(24_suppl_3): S8 - S13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Wekerle Lessons from multiple sclerosis: models, concepts, observations Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii56 - iii60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Terness, T. Oelert, S. Ehser, J. J. Chuang, I. Lahdou, C. Kleist, F. Velten, G. J. Hammerling, B. Arnold, and G. Opelz Mitomycin C-treated dendritic cells inactivate autoreactive T cells: Toward the development of a tolerogenic vaccine in autoimmune diseases PNAS, November 25, 2008; 105(47): 18442 - 18447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The CAMMS223 Trial Investigators Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis N. Engl. J. Med., October 23, 2008; 359(17): 1786 - 1801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Borel, M. Benkhoucha, M. S. Weber, S. S. Zamvil, M.-L. Santiago-Raber, and P. H. Lalive Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model Int. Immunol., October 1, 2008; 20(10): 1313 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R Korenke, M. P Rivey, and D. R Allington Sustained-Release Fampridine for Symptomatic Treatment of Multiple Sclerosis Ann. Pharmacother., October 1, 2008; 42(10): 1458 - 1465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Goodin, B. A. Cohen, P. O'Connor, L. Kappos, and J. C. Stevens Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, September 2, 2008; 71(10): 766 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Ebers, L. Heigenhauser, M. Daumer, C. Lederer, and J. H. Noseworthy Disability as an outcome in MS clinical trials Neurology, August 26, 2008; 71(9): 624 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hestvik, G Skorstad, D. Price, F Vartdal, and T Holmoy Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid Multiple Sclerosis, July 1, 2008; 14(6): 749 - 758. [Abstract] [PDF]
|
|
|
|
|
|
J Petkau, S. Reingold, U Held, G. Cutter, T. Fleming, M. Hughes, D. Miller, H. McFarland, and J. Wolinsky Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses Multiple Sclerosis, July 1, 2008; 14(6): 770 - 778. [Abstract] [PDF]
|
|
|
|
|
|
T Vollmer, H Panitch, A Bar-Or, J Dunn, M. Freedman, S. Gazda, D Campagnolo, F Deutsch, and D. Arnold Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis Multiple Sclerosis, June 1, 2008; 14(5): 663 - 670. [Abstract] [PDF]
|
|
|
|
|
|
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data Multiple Sclerosis, April 1, 2008; 14(3): 370 - 382. [Abstract] [PDF]
|
|
|
|
|
|
C. H. Polman, S. C. Reingold, F. Barkhof, P. A. Calabresi, M. Clanet, J. A. Cohen, G. R. Cutter, M. S. Freedman, L. Kappos, F. D. Lublin, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment Neurology, March 25, 2008; 70(13_Part_2): 1134 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhao, A. Traboulsee, A. J. Petkau, and D. Li Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis Neurology, March 25, 2008; 70(13_Part_2): 1092 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, et al. B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis N. Engl. J. Med., February 14, 2008; 358(7): 676 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.L. Tremlett and J. Oger Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective Multiple Sclerosis, January 1, 2008; 14(1): 94 - 105. [Abstract] [PDF]
|
|
|
|
|
|
B.R. Sajja, P.A. Narayana, J.S. Wolinsky, C.W. Ahn, and t. P. T. M. G. N/A Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study Multiple Sclerosis, January 1, 2008; 14(1): 73 - 80. [Abstract] [PDF]
|
|
|
|
|
|
M. G. Brown, S. Kirby, C. Skedgel, J. D. Fisk, T. J. Murray, V. Bhan, and I. S. Sketris How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology, October 9, 2007; 69(15): 1498 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Thouvenot, D. Hillaire-Buys, M.A. Bos-Thompson, V. Rigau, L. Durand, B. Guillot, and W. Camu Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis Multiple Sclerosis, August 1, 2007; 13(7): 941 - 944. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Glass-Marmor, T. Paperna, Y. Ben-Yosef, and A. Miller Chronotherapy using corticosteroids for multiple sclerosis relapses J. Neurol. Neurosurg. Psychiatry, August 1, 2007; 78(8): 886 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kobayashi, H. Kobayashi, L. Gu, T. Malefyt, and T. J. Siahaan Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 879 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Coyle Evidence-based medicine and clinical trials Neurology, June 12, 2007; 68(24_suppl_4): S3 - S7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Khan Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rovaris, G. Comi, M. Rocca, P. Valsasina, D. Ladkani, E. Pieri, S. Weiss, G. Shifroni, J. Wolinsky, M. Filippi, et al. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial Multiple Sclerosis, May 1, 2007; 13(4): 502 - 508. [Abstract] [PDF]
|
|
|
|
|
|
F. Blanchette Clinical significance of glatiramer acetate antibodies Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35. [Abstract] [PDF]
|
|
|
|
|
|
D. Pohl, E. Waubant, B. Banwell, D. Chabas, T. Chitnis, B. Weinstock-Guttman, S. Tenembaum, and for the International Pediatric MS Study Group Treatment of pediatric multiple sclerosis and variants Neurology, April 17, 2007; 68(16_suppl_2): S54 - S65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cohen, M. Rovaris, A. D. Goodman, D. Ladkani, D. Wynn, M. Filippi, and for the 9006 Study Group Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS Neurology, March 20, 2007; 68(12): 939 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Turley and S. D. Miller Peripheral Tolerance Induction Using Ethylenecarbodiimide-Fixed APCs Uses both Direct and Indirect Mechanisms of Antigen Presentation for Prevention of Experimental Autoimmune Encephalomyelitis J. Immunol., February 15, 2007; 178(4): 2212 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Lily, E McFadden, E Hensor, M Johnson, and H Ford Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment Multiple Sclerosis, November 1, 2006; 12(6): 808 - 813. [Abstract] [PDF]
|
|
|
|
|
|
S Martinez-Yelamos, A Martinez-Yelamos, G M. Ozaeta, V Casado, O Carmona, and T. Arbizu Regression to the mean in multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 826 - 829. [Abstract] [PDF]
|
|
|
|
|
|
J. H. Noseworthy How much can we learn from long-term extension trials in multiple sclerosis? Neurology, September 26, 2006; 67(6): 930 - 931. [Full Text] [PDF]
|
|
|
|
|
|
H. Tremlett and V. Devonshire Is late-onset multiple sclerosis associated with a worse outcome? Neurology, September 26, 2006; 67(6): 954 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, C. H. Polman, T. Haas, A. A. Korn, G. Karlsson, E. W. Radue, et al. Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis N. Engl. J. Med., September 14, 2006; 355(11): 1124 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Trojano, P. Russo, A. Fuiani, D. Paolicelli, E. Di Monte, E. Granieri, G. Rosati, G. Savettieri, G. Comi, P. Livrea, et al. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFN{beta} exposure in multiple sclerosis Multiple Sclerosis, September 1, 2006; 12(5): 578 - 585. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger The value of animal models for drug development in multiple sclerosis Brain, August 1, 2006; 129(8): 1940 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sorensen, N. Koch-Henriksen, M. Ravnborg, J. L. Frederiksen, K a. Jensen, A. Heltberg, H. Schaldemose, S. Deth, O l. Kristensen, M. Worm, et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey Multiple Sclerosis, June 1, 2006; 12(3): 253 - 264. [Abstract] [PDF]
|
|
|
|
|
|
C C Ford, K P Johnson, R P Lisak, H S Panitch, G Shifroni, J S Wolinsky, and The Copaxone(R) Study Group A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients Multiple Sclerosis, June 1, 2006; 12(3): 309 - 320. [Abstract] [PDF]
|
|
|
|
|
|
D. K. Tennakoon, R. S. Mehta, S. B. Ortega, V. Bhoj, M. K. Racke, and N. J. Karandikar Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis. J. Immunol., June 1, 2006; 176(11): 7119 - 7129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Gordon, C. Doorish, J. Montes, R. L. Mosley, B. Diamond, R. B. MacArthur, L. H. Weimer, P. Kaufmann, A. P. Hays, L. P. Rowland, et al. Randomized controlled phase II trial of glatiramer acetate in ALS Neurology, April 11, 2006; 66(7): 1117 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Pittock, B. G. Weinshenker, J. H. Noseworthy, C. F. Lucchinetti, M. Keegan, D. M. Wingerchuk, J. Carter, E. Shuster, and M. Rodriguez Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol, April 1, 2006; 63(4): 611 - 614. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Frohman, E. Havrdova, F. Lublin, F. Barkhof, A. Achiron, M. K. Sharief, O. Stuve, M. K. Racke, L. Steinman, H. Weiner, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol, April 1, 2006; 63(4): 614 - 619. [Full Text] [PDF]
|
|
|
|
|
|
Y. Jee, R. Liu, X.-F. Bai, D. I. Campagnolo, F.-D. Shi, and T. L. Vollmer Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? Int. Immunol., April 1, 2006; 18(4): 537 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Polman, P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., March 2, 2006; 354(9): 899 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Rudick, W. H. Stuart, P. A. Calabresi, C. Confavreux, S. L. Galetta, E.-W. Radue, F. D. Lublin, B. Weinstock-Guttman, D. R. Wynn, F. Lynn, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med., March 2, 2006; 354(9): 911 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kremenchutzky, G. P. A. Rice, J. Baskerville, D. M. Wingerchuk, and G. C. Ebers The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease Brain, March 1, 2006; 129(3): 584 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Racke, A. R. Gocke, M. Muir, A. Diab, P. D. Drew, and A. E. Lovett-Racke Nuclear Receptors and Autoimmune Disease: The Potential of PPAR Agonists to Treat Multiple Sclerosis J. Nutr., March 1, 2006; 136(3): 700 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S L Minden, D Frankel, L Hadden, J Perloff, K P Srinath, and D C Hoaglin The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics Multiple Sclerosis, February 1, 2006; 12(1): 24 - 38. [Abstract] [PDF]
|
|
|
|
|
|
W. Pollmann, L.-P. Erasmus, W. Feneberg, and A. Straube The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS Neurology, January 24, 2006; 66(2): 275 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Held, L. Heigenhauser, C. Shang, L. Kappos, C. Polman, and for the Sylvia Lawry Centre for MS Research Predictors of relapse rate in MS clinical trials Neurology, December 13, 2005; 65(11): 1769 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R A Rudick, G R Cutter, M Baier, B Weinstock-Guttman, M K Mass, E Fisher, D M Miller, and A W Sandrock Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients Multiple Sclerosis, December 1, 2005; 11(6): 626 - 634. [Abstract] [PDF]
|
|
|
|
|
|
J Haas, M Maas-Enriquez, and H P Hartung Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years Multiple Sclerosis, October 1, 2005; 11(5): 562 - 567. [Abstract] [PDF]
|
|
|
|
|
|
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations Arch Neurol, October 1, 2005; 62(10): 1519 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Zajicek Diagnosis and disease modifying treatments in multiple sclerosis Postgrad. Med. J., September 1, 2005; 81(959): 556 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Ghezzi, M P Amato, M Capobianco, P Gallo, G Marrosu, V Martinelli, N Milani, C Milanese, L Moiola, F Patti, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study Multiple Sclerosis, August 1, 2005; 11(4): 420 - 424. [Abstract] [PDF]
|
|
|
|
|
|
C. E. Smith, T. N. Eagar, J. L. Strominger, and S. D. Miller Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis PNAS, July 5, 2005; 102(27): 9595 - 9600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R Jeffery, N. Chepuri, D. Durden, and J. Burdette A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging Multiple Sclerosis, June 1, 2005; 11(3): 296 - 301. [Abstract] [PDF]
|
|
|
|
|
|
J. Rio, J. Porcel, N. Tellez, A. Sanchez-Betancourt, M a. Tintore, M J. Arevalo, C. Nos, and X. Montalban Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis Multiple Sclerosis, June 1, 2005; 11(3): 306 - 309. [Abstract] [PDF]
|
|
|
|
|
|
N. J. Karandikar and M. K. Racke Glatiramer Acetate Therapy: The Plot Thickens Arch Neurol, June 1, 2005; 62(6): 858 - 859. [Full Text] [PDF]
|
|
|
|
|
|
S Nolden, C Casper, A Kuhn, and H F Petereit Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate Multiple Sclerosis, April 1, 2005; 11(2): 245 - 248. [Abstract] [PDF]
|
|
|
|
|
|
C. D. Margot, M. L. Ford, and B. D. Evavold Amelioration of Established Experimental Autoimmune Encephalomyelitis by an MHC Anchor-Substituted Variant of Proteolipid Protein 139-151 J. Immunol., March 15, 2005; 174(6): 3352 - 3358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Blair, M. E. Pease, J. Hammond, D. Valenta, J. Kielczewski, H. Levkovitch-Verbin, and H. Quigley Effect of Glatiramer Acetate on Primary and Secondary Degeneration of Retinal Ganglion Cells in the Rat Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 884 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. H. Stern, Z. Illes, J. Reddy, D. B. Keskin, M. Fridkis-Hareli, V. K. Kuchroo, and J. L. Strominger Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis PNAS, February 1, 2005; 102(5): 1620 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Cohen, O. Khan, D. R. Jeffery, K. Bashir, S. A. Rizvi, E. J. Fox, M. Agius, R. Bashir, T. E. Collins, R. Herndon, et al. Identifying and treating patients with suboptimal responses Neurology, December 28, 2004; 63(12_suppl_6): S33 - S40. [Abstract] [Full Text]
|
|
|
|
|
|
W. H. Stuart Current clinical perspectives on the treatment of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S1 - S2. [Full Text]
|
|
|
|
|
|
W. H. Stuart, S. Cohan, J. R. Richert, and A. Achiron Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S19 - S27. [Abstract] [Full Text]
|
|
|
|
|
|
A. Langer-Gould, H. H. Moses, and T. J. Murray Strategies for managing the side effects of treatments for multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S35 - S41. [Abstract] [Full Text]
|
|
|
|
|
|
M. Sela and E. Mozes Therapeutic vaccines in autoimmunity PNAS, October 5, 2004; 101(suppl_2): 14586 - 14592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hohlfeld and H. Wekerle Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines PNAS, October 5, 2004; 101(suppl_2): 14599 - 14606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T L Vollmer, J T Phillips, A D Goodman, M A Agius, M A Libonati, J L Giacchino, and J S Grundy An open-label safety and drug interaction study of natalizumab (AntegrenTM) in combination with interferon-beta (Avonex(R)) in patients with multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 511 - 520. [Abstract] [PDF]
|
|
|
|
|
|
Z. Illes, J. N. H. Stern, J. Reddy, H. Waldner, M. P. Mycko, C. F. Brosnan, S. Ellmerich, D. M. Altmann, L. Santambrogio, J. L. Strominger, et al. Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells PNAS, August 10, 2004; 101(32): 11749 - 11754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M J Tullman, R J Oshinsky, F D Lublin, and G R Cutter Clinical characteristics of progressive relapsing multiple sclerosis Multiple Sclerosis, August 1, 2004; 10(4): 451 - 454. [Abstract] [PDF]
|
|
|
|
|
|
L M Metz, S B Patten, C J Archibald, J I Bakker, C J Harris, D G Patry, R B Bell, M Yeung, W F Murphy, C A Stoian, et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue J. Neurol. Neurosurg. Psychiatry, July 1, 2004; 75(7): 1045 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F G Maggs and J Palace The pathogenesis of multiple sclerosis: is it really a primary inflammatory process? Multiple Sclerosis, June 1, 2004; 10(3): 326 - 329. [Abstract] [PDF]
|
|
|
|
|
|
M. S. Weber, M. Starck, S. Wagenpfeil, E. Meinl, R. Hohlfeld, and C. Farina Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo Brain, June 1, 2004; 127(6): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Kim, I. Ifergan, J. P. Antel, R. Seguin, M. Duddy, Y. Lapierre, F. Jalili, and A. Bar-Or Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis J. Immunol., June 1, 2004; 172(11): 7144 - 7153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Stuve, M. Kita, D. Pelletier, R. J Fox, J. Stone, D. E Goodkin, and S. S Zamvil Mitoxantrone as a potential therapy for primary progressive multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(1_suppl): S58 - S61. [Abstract] [PDF]
|
|
|
|
|
|
S. J. Pittock, W. T. Mayr, R. L. McClelland, N. W. Jorgensen, S. D. Weigand, J. H. Noseworthy, and M. Rodriguez Quality of Life Is Favorable for Most Patients With Multiple Sclerosis: A Population-based Cohort Study Arch Neurol, May 1, 2004; 61(5): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Stuve, M. Kita, D. Pelletier, R. J Fox, J. Stone, D. E Goodkin, and S. S Zamvil Mitoxantrone as a potential therapy for primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S58 - S61. [Abstract] [PDF]
|
|
|
|
|
|
P. Rudge Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis? Multiple Sclerosis, April 1, 2004; 10(2): 123 - 125. [PDF]
|
|
|
|
|
|
S. J. Pittock, W. T. Mayr, R. L. McClelland, N. W. Jorgensen, S. D. Weigand, J. H. Noseworthy, and M. Rodriguez Disability profile of MS did not change over 10 years in a population-based prevalence cohort Neurology, February 24, 2004; 62(4): 601 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Pittock, W. T. Mayr, R. L. McClelland, N. W. Jorgensen, S. D. Weigand, J. H. Noseworthy, B. G. Weinshenker, and M. Rodriguez Change in MS-related disability in a population-based cohort: A 10-year follow-up study Neurology, January 13, 2004; 62(1): 51 - 59. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
